Parashar Nirbhay, Amidon Matthew, Milad Abdulhamid, Devine Adam, Yi Li, Penk Jamie
Department of Pediatric Cardiology, Advocate Children's Heart Institute, Oak Lawn, IL, USA.
Department of Pediatrics, Advocate Children's Heart Institute, Oak Lawn, IL, USA.
World J Pediatr Congenit Heart Surg. 2019 Sep;10(5):565-571. doi: 10.1177/2150135119859879.
Extubation failure rates for critical patients in pediatric intensive care units (ICUs) range from 5% to 29%. Noninvasive (NIV) ventilation has been shown to decrease extubation failure. We compared reintubation rates and outcomes of patients supported with NIV neurally adjusted ventilation assist (NAVA) versus historical controls supported with high-flow nasal cannula (HFNC).
Case-control study of infants less than three months of age who underwent cardiac surgery and received NIV support after extubation from January 2011 to May 2017. All patients supported with NIV NAVA after it became available in September 2013 were compared to matched patients extubated to HFNC from prior to September 2013.
Forty-two patients identified for the NIV NAVA group were matched with 42 historical controls supported with HFNC. Groups had similar baseline characteristics based on rate of acute kidney injury, number of single ventricle patients, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) category, age, weight, bypass time, and duration of intubation. There was no significant difference in reintubation rates within 72 hours (14.3% in the HFNC group and 16.7% in the NIV NAVA group, = 1.0). Median duration from extubation to coming off NIV support was longer in the NIV NAVA group (3.6 days vs 0.6 days, < .001). Median time from extubation to ICU discharge was longer in the NIV NAVA group (10.5 vs 6.8 days, = .02), as was total postoperative ICU length of stay (LOS; 17.6 vs 12.2, = .01).
Introduction of NIV NAVA for postextubation support did not reduce reintubation rates compared to HFNC. Further study is needed as adoption of NIV NAVA may prolong LOS.
儿科重症监护病房(ICU)中危重症患儿的拔管失败率在5%至29%之间。无创(NIV)通气已被证明可降低拔管失败率。我们比较了接受神经调节通气辅助(NAVA)的NIV支持患者与接受高流量鼻导管(HFNC)支持的历史对照患者的再次插管率和结局。
对2011年1月至2017年5月接受心脏手术并在拔管后接受NIV支持的3个月以下婴儿进行病例对照研究。将2013年9月NAVA可用后接受NIV NAVA支持的所有患者与2013年9月之前拔管至HFNC的匹配患者进行比较。
NIV NAVA组确定的42例患者与42例接受HFNC支持的历史对照患者相匹配。根据急性肾损伤发生率、单心室患者数量、胸外科医师协会-欧洲心胸外科学会(STAT)分类、年龄、体重、体外循环时间和插管持续时间,两组具有相似的基线特征。72小时内的再次插管率无显著差异(HFNC组为14.3%,NIV NAVA组为16.7%,P = 1.0)。NIV NAVA组从拔管到停止NIV支持的中位持续时间更长(3.6天对0.6天,P <.001)。NIV NAVA组从拔管到ICU出院的中位时间更长(10.5天对6.8天,P =.02),术后ICU总住院时间(LOS)也是如此(17.6天对12.2天,P =.01)。
与HFNC相比,引入NIV NAVA进行拔管后支持并未降低再次插管率。由于采用NIV NAVA可能会延长住院时间,因此需要进一步研究。